Fundraising Fox
Compass Therapeutics
NASDAQ: CMPXCambridge, US · Founded 2014 · Incorporated in Delaware · 61 employees on LinkedIn · 10 known investors
Find your way into Compass Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Chaya Patel to introduce you to Errik Anderson
You →Chaya · together at Ulysses Diversified Holdings →Errik
Ask Jamie Chen to introduce you to Schuetz Thomas
You →Jamie · together at Enobia Pharma →Schuetz
Ask Sam Okafor to introduce you to Neil Lerner
You →Sam · together at Compass Therapeutics →Neil
- Arjun Prasad216 people can intro you
Sign up to find every way you can get introduced to Compass Therapeutics
- Your email: who you already know at Compass Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Compass Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations. Its pipeline focuses on immuno-oncology therapies that bridge the innate and adaptive immune systems by targeting T cells, NK cells, and macrophages.
Founders & leadership
Compass Therapeutics was founded in 2014 by Schuetz Thomas, Errik Anderson, and Thomas J. Schuetz.
Board
Investors · 10
How we know: av.vc · Not right? Tell us
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · Not right? Tell us
How we know: OrbiMed's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: venBio Partners's portfolio page · Not right? Tell us
How we know: Vivo Capital's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$388.4M disclosed across 5 of 7 rounds · 1900–2020
▶$195.3MraisedJul 2020 · 114 investors · OtherRule 506(b)
- Vered Bisker-LeibExecutive Officer
- Carl L. GordonDirector
- Julie SunderlandDirector
- Stephen P. SquintoDirector
- Philip FerneauDirector
- Thomas J. SchuetzExecutive Officer, Director
- Offering amount
- $195.3M
- Amount sold
- $195.3M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$60.5MraisedJul 2020 · 110 investors · OtherRule 506(b)
- Stephen P. SquintoDirector
- Julie SunderlandDirector
- Thomas J. SchuetzExecutive Officer, Director
- Vered Bisker-LeibExecutive Officer
- Carl L. GordonDirector
- Philip FerneauDirector
- Offering amount
- $70M
- Amount sold
- $60.5M
- Sales commissions
- $4.7M
- Placement agents
- Katalyst Securities LLC, B. Riley FBR, Inc., Raymond James & Associates, Inc.
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$110.2MraisedJul 2018 · 20 investors · BiotechnologyRule 506(b)
- VERED BISKER-LEIBExecutive Officer
- TIMOTHY ANDERSONDirector
- PIOTR BOBROWICZExecutive Officer
- PHILIP FERNEAUDirector
- CARL GORDONDirector
- DAMON BANKSExecutive Officer
- THOMAS J. SCHUETZExecutive Officer, Director, Promoter
- STEVEN SQUINTODirector
- ERRIK ANDERSONDirector, Promoter
- SARA MANNLEExecutive Officer
- JEB LEDELLExecutive Officer
- STEVE TREGAYDirector
- BEN AUSPITZDirector
- Offering amount
- $170.2M
- Amount sold
- $110.2M
- Proceeds to insiders
- $1.7M
- First sale
- Jun 2015
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
▶$21.8MraisedJan 2018 · 14 investors · BiotechnologyRule 506(b)
- THOMAS J SCHUETZExecutive Officer, Director, Promoter
- STEVEN SQUINTODirector
- CARL GORDONDirector
- SARA MANNLEExecutive Officer
- VERED BISKER-LEIBExecutive Officer
- ERRIK ANDERSONDirector, Promoter
- BEN AUSPITZDirector
- BRUCE STEELDirector
- JEB LEDELLExecutive Officer
- DAMON BANKSExecutive Officer
- WILL EDENDirector
- PIOTR BOBROWICZExecutive Officer
- STEVE TREGAYDirector
- PHILIP FERNEAUDirector
- Offering amount
- $50M
- Amount sold
- $21.8M
- First sale
- Dec 2017
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
▶$575KraisedMay 2015 · 4 investors · BiotechnologyRule 506(b)
- Schuetz ThomasExecutive Officer, Director
- Errik AndersonExecutive Officer, Director
- Steve TregayDirector
- Offering amount
- $1M
- Amount sold
- $575K
- First sale
- May 2014
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Compass Therapeutics.
In the news
Frequently asked questions
- What does Compass Therapeutics do?
- Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations. Its pipeline focuses on immuno-oncology therapies that bridge the innate and adaptive immune systems by targeting T cells, NK cells, and macrophages.
- Who founded Compass Therapeutics?
- Compass Therapeutics was founded by Schuetz Thomas, Errik Anderson, Thomas J. Schuetz in 2014.
- Who are Compass Therapeutics's investors?
- Compass Therapeutics's investors include Alumni Ventures, BioBrit, F-Prime Capital, Foresite Capital, GV (Google Ventures), OrbiMed, venBio Partners, Vivo Capital and 2 more.
- How much funding has Compass Therapeutics raised?
- Compass Therapeutics has disclosed $388.4M raised across 5 of its 7 known rounds.
- Where is Compass Therapeutics headquartered?
- Compass Therapeutics is headquartered in Cambridge, US.